Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Blind, Controlled Study to Evaluate the Effectiveness of the Use of Bone Marrow-Derived Mesenchymal Stem Cells (MSCs) in Fibrin in the Treatment of Chronic Wounds|
- Wound closure [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
- Overall rate of wound healing reduction [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||June 2010|
|Study Completion Date:||June 2015|
|Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
Placebo Comparator: Standard therapy and control saline spray
Conventional standard therapy and control saline spray
|Genetic: Stem Cell|
Sham Comparator: standard therapy and fibrin spray
Conventional standard therapy and fibrin spray
|Genetic: Stem Cell|
Experimental: Conventional standard therapy and MSCs
Conventional Standard Therapy and MSCs (autologous bone marrow-derived mesenchymal stem cells) in fibrin spray.
|Genetic: Stem Cell|
Hide Detailed Description
Sixty-six (66) subjects are planned to be enrolled into the trial. each subject's duration of participation will be 24 weeks on therapy with a 4 week post-treatment visit. A run-in phase of 2 weeks will be required prior to randomization/enrollment.
All subjects will receive appropriate and standard care for chronic wounds, including dressings, bandages, and off-loading, if required. All subjects will receive either saline, fibrin or MSCs in fibrin using an identical double-barreled syringe to keep the blind. Therefore, subjects will then be randomized to one of three groups:
- conventional standard therapy and control saline spray
- conventional standard therapy and fibrin spray
- conventional standard therapy and MSCs (autologous bone marrow-derived mesenchymal stem cell)in fibrin spray
All inclusion and exclusion information will be reviewed to make sure that the subject is eligible for entry into the study. The following procedures will be performed during this two week period:
Biopsy - One (3 x 6 mm) biopsy will be taken from the edge of the wound for additional diagnostic tests and for culturing of cells. The second (3-4 mm) biopsy will be taken from the thigh for culturing of cells in the laboratory to assess the healing process. The thigh biopsy will then be excised by taking about 3/4 inch long by 1/4 inch wide margin from around it, and suturing it closed. The reason for this biopsy of the normal skin is so that it can be used to compare the healing process to the chronic wound.
Blood Sampling - Blood will be drawn for laboratory testing to assess the overall well-being, HIV, Hepatitis B & C and if the subject is a woman able to bear children, to test for pregnancy.
Wound Measurements - Wound measurements will be taken to determine the size of the wound and to assess for healing.
If the wound has not reduced significantly in size, and the subject is still eligible for the study; he/she will be assigned to a study treatment. The decision as to which treatment he/she will receive will be determined by a process called randomization. Randomization is a mathematical process used to guarantee that each participant in the study has an equal chance of being assigned to any of the treatment options available.
The treatment groups that the subject may be assigned to are as follows:
Group #1 - Conventional Therapy and Control Saline Spray -The subject will receive conventional therapy, wound measurements, photography and observations. At the Day 1 treatment visit a double-barrel syringe system will be used to deliver topically normal saline to the wound. Up to 2 additional treatments will be applied at Weeks 3 & 6 (+ or - 2 or 3 days).
Group #2 -Conventional Therapy and Fibrin Spray - The subject will receive conventional therapy, wound measurements, photography, and observations. At the Day 1 treatment visit a double-barrel syringe system will be used to deliver topically fibrin alone to the wound. Up to 2 additional treatments will be applied at Weeks 3 & 6 (+ or - 2 or 3 days).
Group #3 - Conventional Therapy and Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin Spray - The subject will receive conventional therapy, wound measurements, photography and observations. At the Day 1 treatment visit a double-barrel syringe system will be used to deliver topically autologous bone marrow-derived mesenchymal stem cells in fibrin. Up to 2 additional treatments will be applied at Weeks 3 & 6 (+ or - 2 or 3 days) if your wound is not healed.
Conventional Therapy - The subject will receive standard of care and accepted conventional therapy, regardless of which of the three groups you will be randomized in. This standard of care involves the use of dressings, bandages and protective ways to increase healing of your wound.
Bone Marrow Aspirate - Depending on the treatment group that the subject is assigned to, they will have either a bone marrow aspirate and/or sham (imitation) aspirate performed at this visit.
Day 1 Treatment Visit:
All groups will receive the study treatment that was assigned at the randomization visit. Wound measurements, clinical observations, wound dressings, adverse event reporting and photography will be performed.
Weekly Follow-up Visits (Weeks 1-24):
All groups will return weekly for conventional therapy, wound measurements, clinical observations, wound dressing changes, adverse event report, and photography. Two additional study treatments will be given at Weeks 3 & 6 (+ or - 2 or 3 days) if the wound is not healed.
Post-Treatment Follow-up Visit (Week 28):
All groups will return one month after 24 weeks of treatment for evaluation, wound measurements, and photography.
Follow-up wound Biopsies:
Participants in all three study treatment groups will be asked to have an additional biopsy of the wound edge at Week 6. This biopsy will only be taken if the wound has not healed.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01751282
|United States, Rhode Island|
|Roger Williams Medical Center|
|Providence, Rhode Island, United States, 02908|
|Principal Investigator:||Vincent Falanga, MD||Roger Williams Medical Center|